But while peptides can support weight loss, how well they work depends on the specific type, dose, and adherence
They were initially developed to manage type 2 diabetes, but are now being explored for a broader range of uses, most popularly, in weight management but also importantly, in cardiovascular health
For those new to peptide injections , starting with the abdomen typically provides the most consistent absorption and the easiest self-administration angle
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
For example, can tirzepatide cause blurry vision
Start Your Transformation Take the first step toward lasting results
